Immunosuppressive therapy for autoimmune inner ear disease

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 425-434

  Buniel, Maria C ^a   Geelan Hansen, Katie ^a   Weber, Peter C ^a   Tuohy, Vincent K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmunity; Corticosteroid; Hearing loss; Immunomodulation; Immunosuppression

Indexed keywords

ALDOSTERONE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; FLUOROURACIL; INFLIXIMAB; KEYHOLE LIMPET HEMOCYANIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNER EAR DISEASE; LABYRINTHITIS; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; REVIEW;

ADRENAL CORTEX HORMONES; AUTOIMMUNE DISEASES; BIOMEDICAL RESEARCH; HEARING LOSS, SENSORINEURAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LABYRINTH DISEASES; MODELS, ANIMAL;

EID: 77953458311     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.12     Document Type: Review

References (66)

1. McCabe BF: Autoimmune sensorineural hearing loss. Ann. Otol. Rhinol. Laryngol. 88(5 Pt 1), 585-589 (1979).
2. Hughes GB, Kinney SE, Barna BP, Calabrese LH: Practical versus theoretical management of autoimmune inner ear disease. Laryngoscope. 94(6), 758-767 (1984).
3. Loveman DM, de Comarmond C, Cepero R, Baldwin DM: Autoimmune sensorineural hearing loss: clinical course and treatment outcome. Semin. Arthritis Rheum. 34(2), 538-543 (2004).
4. Hughes GB, Kinney SE, Barna BP, Calabrese LH: Autoimmunity in otology. Am. J. Otol. 7(3), 197-199 (1986).
5. Harris JP: Immunology of the inner ear: response of the inner ear to antigen challenge. Otolaryngol. Head Neck Surg. 91(1), 18-32 (1983).
6. Harris JP: Immunology of the inner ear: evidence of local antibody production. Ann. Otol. Rhinol. Laryngol. 93(2 Pt 1), 157-162 (1984).
7. Takahashi M, Harris JP: Analysis of immunocompetent cells following inner ear immunostimulation. Laryngoscope 98(10), 1133-1138 (1988). (Pubitemid 18244330)
8. Ma C, Billings P, Harris JP, Keithley EM: Characterization of an experimentally induced inner ear immune response. Laryngoscope 110(3 Pt 1), 451-456 (2000). (Pubitemid 30143693)
9. Singer GG, Carrera AC, Marshak-Rothstein A, Martínez C, Abbas AK: Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr. Opin. Immunol. 6(6), 913-920 (1994).
10. Trune DR, Craven JP, Morton JI, Mitchell C: Autoimmune disease and cochlear pathology in the C3H/lpr strain mouse. Hear. Res. 38(1-2), 57-66 (1989
11. Kusakari C, Hozawa K, Koike S, Kyogoku M, Takasaka T: MRL/MP-lpr/lpr mouse as a model of immune-induced sensorineural hearing loss. Ann. Otol. Rhinol. Laryngol. Suppl. 157, 82-86 (1992). ■ Early description of the MRL/lpr model of a 'secondary' form of autoimmune inner ear disease (AIED).
12. Ruckenstein MJ, Milburn M, Hu L: Striai dysfunction in the MRL-Fas mouse. Otolaryngol. Head Neck Surg. 121(4), 452-456 (1999).
13. Harris JP: Experimental autoimmune sensorineural hearing loss. Laryngoscope 97(1), 63-76 (1987). ■ Early description of the keyhole limpet hemocyanin (KLH) model of AIED, a model frequently used to test efficacy of therapeutic interventions.
14. Soliman AM: Experimental autoimmune inner ear disease. Laryngoscope 99(2), 188-193 (1989).
15. Yamanobe S, Harris JP: Spontaneous remission in experimental autoimmune labyrinthitis. Ann. Otol. Rhinol. Laryngol. 101(12), 1007-1014 (1992).
16. Tomiyama S, Jinnouchi K, Ikezono T, Pawankar R, Yagi T: Experimental autoimmune labyrinthitis induced by cell-mediated immune reaction. Acta Otolaryngol. 119(6), 665-670 (1999). (Pubitemid 29513777)
17. Garcia-Berrocal JR, Ramirez-Camacho R, Trinidad A, Zurita M, de la Fuente R, Lobo D: Controversies and criticisms on designs for experimental autoimmune labyrinthitis. Ann. Otol. Rhinol. Laryngol. 113(5), 404-410 (2004).
18. Gloddek B, Gloddek J, Arnold W: Induction of an inner-ear-specific autoreactive T-cell line for the diagnostic evaluation of an autoimmune disease of the inner ear. Ann. NY Acad. Sci. 830, 266-276 (1997).
19. Ikezono T, Tomiyama S, Pawankar R, Jinnouchi K, Suzuki Y, Yagi T: Passive transfer of experimental autoimmune labyrinthitis. Audiol. Neurootol. 5(5), 292-299 (2000).
20. + T cells specific for inner ear peptides. J. Clin. Invest. 113(8), 1210-1217 (2004). ■ Description of a model for primary AIED involving immunization of mice against cochlin, an abundantly expressed inner ear-specific protein.
21. Ikezono T, Omori A, Ichinose S, Pawankar R, Watanabe A, Yagi T: Identification of the protein product of the Coch gene (hereditary deafness gene) as the major component of bovine inner ear protein. Biochim. Biophys. Acta. 1535(3), 258-265 (2001).
22. Baek MJ, Park HM, Johnson JM et al.: Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss. J. Immunol. 177(6), 4203-4210 (2006).
23. Ruckenstein MJ, Sarwar A, Hu L, Shami H, Marion TN: Effects of immunosuppression on the development of cochlear disease in the MRL-Fas(lpr) mouse. Laryngoscope 109(4), 626-630 (1999). (Pubitemid 29165916)
24. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH: Steroid treatment in young MRL.MpJ-Fas(lpr) autoimmune mice prevents cochlear dysfunction. Hear. Res. 137(1-2), 167-173 (1999).
25. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH: Steroid treatment improves cochlear function in the MRL.MpJ-Fas(lpr) autoimmune mouse. Hear. Res. 137(1-2), 160-166 (1999). ■ Therapeutic intervention study in the MRL/lpr mouse model of AIED with steroids.
26. Rupprecht R, Reul JM, van Steensel B et al.: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur. J. Pharmacol. 247(2), 145-154 (1993).
27. Trune DR, Kempton JB, Kessi M: Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Faslpr autoimmune mice. Laryngoscope 110(11), 1902-1906 (2000).
28. Trune DR, Kempton JB, Gross ND: Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hear. Res. 212(1-2), 22-32 (2006).
29. Trune DR, Kempton JB: Aldosterone and prednisolone control of cochlear function in MRL/MpJ-Fas(lpr) autoimmune mice. Hear. Res. 155(1-2), 9-20 (2001).
30. Mousa SA, Goncharuk O, Miller D: Recent advances of TNF-α antagonists in rheumatoid arthritis and chronic heart failure. Expert Opin. Biol. Ther. 7(5), 617-625 (2007).
31. Satoh H, Firestein GS, Billings PB, HarrisJP, Keithley EM: Tumor necrosis factor-α, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope 112(9), 1627-1634 (2002). (Pubitemid 34977568)
32. Peppel K, Crawford D, Beutler B: A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174(6), 1483-1489 (1991).
33. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM: Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. J. Assoc. Res. Otolaryngol. 4(2), 139-147 (2003).
34. Wang X, Truong T, Billings PB, Harris JP, Keithley EM: Blockage of immune-mediated inner ear damage by etanercept. Otol. Neurotol. 24(1), 52-57 (2003). ■■ Study in the KLH model of AIED describing the effect of a TNF-α inhibitor on inner ear damage, delivered both systemically and via intratympanic injections.
35. Lobo D, Trinidad A, Garcia-Berrocal JR, Verdaguer JM, Ramirez-Camacho R: TNF-α blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis. Eur. Arch. Otorhinolaryngol. 263(7), 622-626 (2006). ■ Animal study in the KLH model of AIED comparing the efficacy of TNF-α blockers and glucocorticoids, demonstrating that the two treatments are equally therapeutic.
36. McCabe BF: Autoimmune inner ear disease: therapy. Am. J. Otol. 10(3), 196-197 (1989).
37. Ruckenstein MJ.: Autoimmune inner ear disease. Curr. Opin. Otolaryngol. Head Neck Surg. 12(5), 426-430 (2004).
38. Ryan AF, Harris JP, Keithley EM: Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol. 548 (Suppl.), 38-43 (2002). ■ Comprehensive review of disease mechanism and treatment options.
39. Rahman MU, Poe DS, Choi HK: Autoimmune vestibulo-cochlear disorders. Curr. Opin. Rheumatol. 13(3), 184-189 (2001).
40. Broughton SS, Meyerhoff WE, Cohen SB: Immune-mediated inner ear disease: 10-year experience. Semin. Arthritis Rheum. 34(2), 544-548 (2004).
41. Zeitoun H, Beekman JG, Arts HA et al.: Corticosteroid response and supporting cell antibody in autoimmune hearing loss. Arch. Otolaryngol. Head Neck Surg. 131(8), 665-672 (2005).
42. Stone JH, Francis HW: Immune-mediated inner ear disease. Curr. Opin. Rheumatol. 12(1), 32-40 (2000).
43. Sismanis A, Wise CM, Johnson GD: Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg. 116(2), 146-152 (1997). (Pubitemid 27097536)
44. Moscicki RA, San Martin JE, Quintero CH, Rauch SD, Nadol JB Jr, Bloch KJ: Serum antibody to inner ear proteins in patients with progressive hearing loss. Correlation with disease activity and response to corticosteroid treatment. JAMA 272(8), 611-616 (1994).
45. Matteson EL, Tirzaman O, Facer GW et al.: Use of methotrexate for autoimmune hearing loss. Ann. Otol. Rhinol. Laryngol. 109(8 Pt 1), 710-714 (2000).
46. Matteson EL, Fabry DA, Facer GW et al.: Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis Rheum. 45(2), 146-150 (2001).
47. Salley LH,Jr, Grimm M, Sismanis A, Spencer RF, Wise CM: Methotrexate in the management of immune mediated cochleovesitibular disorders: clinical experience with 53 patients. J. Rheumatol. 28(5), 1037-1040 (2001). (Pubitemid 32422585)
48. Harris JP, Weisman MH, Derebery JM et al.: Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA. 290(14), 1875-1883 (2003). ■■ Randomized controlled trial of methotrexate in AIED.
49. Rahman MU, Poe DS, Choi HK: Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol. Neurotol. 22(5), 619-624 (2001).
50. Matteson EL, Choi HK, Poe DS et al.: Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 53(3), 337-342 (2005).
51. Cohen S, Shoup A, Weisman MH, Harris J: Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol. Neurotol. 26(5), 903-907 (2005).
52. Lasak JM, Sataloff RT, Hawkshaw M, Carey TE, Lyons KM, Spiegel JR: Autoimmune inner ear disease: steroid and cytotoxic drug therapy. Ear Nose Throat J. 80(11), 808-811, 815-816, 818 passim (2001). (Pubitemid 33078840)
53. Saracaydin A, Katircioglu S, Katircioglu S, Karatay MC: Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease. J. Int. Med. Res. 21(4), 192-196 (1993).
54. Street I, Jobanputra P, Proops DW: Etanercept, a tumour necrosis factor α receptor antagonist, and methotrexate in acute sensorineural hearing loss. J. Laryngol. Otol. 120(12), 1064-1066 (2006).
55. Luetje CM, Berliner KI: Plasmapheresis in autoimmune inner ear disease: long-term follow-up. Am. J. Otol. 18(5), 572-576 (1997).
56. Goycoolea MV: Clinical aspects of round window membrane permeability under normal and pathological conditions. Acta Otolaryngol. 121(4), 437-447 (2001).
57. Parnes LS, Sun AH, Freeman DJ: Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 109(7 Pt 2), 1-17(1999). ■ Discussion of cochlear pharmacokinetics and intratympanic clinical application
58. Chandrasekhar SS, Rubinstein RY, Kwartler JA et al.: Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg. 122(4), 521-528 (2000).
59. Liu HJ, Dong MM, Chi FL: Dexamethasone pharmacokinetics in guinea pig inner ear perilymph. ORL J. Otorhinolaryngol. Relat. Spec. 68(2), 93-98 (2006).
60. Yang J, Wu H, Zhang P, Hou DM, Chen J, Zhang SG: The pharmacokinetic profiles of dexamethasone and methylprednisolone concentration in perilymph and plasma following systemic and local administration. Acta Otolaryngol. 128(5), 496-504 (2008). (Pubitemid 351550959)
61. Yang GS, Song HT, Keithley EM, Harris JP: Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. Am. J. Otol. 21(4), 499-504 (2000).
62. Barkdull GC, Hondarrague Y, Meyer T, Harris JP, Keithley EM: AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis. Laryngoscope 117(12), 2174-2182 (2007). (Pubitemid 351339593)
63. Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Srein I: Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J. 75(8), 468-471 (1996). (Pubitemid 26278192)
64. Garcia-Berrocal JR, Ibanez A, Rodriguez A et al.: Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: a physiopathologic approach. Eur. Arch. Otorhinolaryngol. 263(11), 977-982 (2006).
65. Van Wijk F, Staecker H, Keithley E, Lefebvre PP: Local perfusion of the tumor necrosis factor α blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol. Neurootol. 11(6), 357-365 (2006). ■ Pilot study on the use of the intratympanic TNF-α inhibitor infliximab in AIED.
66. Niparko JK, Wang NY, Rauch SD et al.: Serial audiometry in a clinical trial of AIED treatment. Otol. Neurotol. 26(5), 908-917 (2005).